Boehringer Ingelheim and CureVac announce collaboration to develop next generation lung cancer immunotherapy
19 September 2014 | By Boehringer Ingelheim
Boehringer Ingelheim and CureVac, leader in mRNA (messenger ribonucleic acid)-based drug development, jointly announce an exclusive global license and development collaboration...